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Primary systemic therapy (PST) for operable breast cancer enables the identification of in vivo biological markers that predict response
to treatment. A total of 118 patients with T2–4 N0–1 M0 primary breast cancer received six cycles of anthracycline-based PST.
Clinical and radiological response was assessed before and after treatment using UICC criteria. A grading system to score pathological
response was devised. Diagnostic biopsies and postchemotherapy surgical specimens were stained for oestrogen (ER) and
progesterone (PgR) receptor, HER-2 and cell proliferation (Ki-67). Clinical, radiological and pathological response rates were 78, 72
and 38%, respectively. There was a strong correlation between ER and PgR staining (Po0.0001). Higher Ki-67 proliferation indices
were associated with PgR  tumours (median 28.3%, PgRþ 22.9%; P¼0.042). There was no relationship between HER-2 and other
biological markers. No single pretreatment or postchemotherapy biological parameter predicted response by any modality of
assessment. In all, 10 tumours changed hormone receptor classification after chemotherapy (three ER, seven PgR); HER-2 staining
changed in nine cases. Median Ki-67 index was 24.9% before and 18.1% after treatment (P¼0.02); the median reduction in Ki-67
index after treatment was 21.2%. Tumours displaying 475% reduction in Ki-67 after chemotherapy were more likely to achieve a
pathological response (77.8 vs 26.7%, P¼0.004).
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Neoadjuvant chemotherapy or primary systemic therapy (PST) for
operable breast cancer provides an opportunity to evaluate
biological markers that may predict response to treatment. The
identification of tumour parameters that accurately predict
response to treatment would be of value in optimising PST so
that nonresponders could be offered alternative and more effective
therapies.
Biological markers used in routine clinical practice were selected
for the purposes of this analysis. Oestrogen receptor (ER) and
progesterone receptor (PgR) status are widely used to select
patients for adjuvant hormonal therapy (Allred et al, 1998;
EBCTCG, 1998; Harvey et al, 1999) and may predict response to
cytotoxic chemotherapy in metastatic disease (Kiang et al, 1978;
Lippman et al, 1978; Lippman and Allegra, 1980), but their role in
predicting response to primary chemotherapy remains controver-
sial. Human epidermal growth factor (HER-2) overexpression has
been associated with poor overall prognosis, shorter relapse-free
and overall survival (Slamon et al, 1987), sensitivity to optimal
dose anthracycline chemotherapy (Thor et al, 1998) and resistance
to adjuvant anthracycline chemotherapy and tamoxifen (Willsher
et al, 1998; Gregory et al, 2000). Immunohistochemical staining for
Ki-67, a nuclear antigen expressed in cycling cells, allows the
proliferation index of tumours to be estimated on paraffin-
embedded tissue sections. Higher responses to chemotherapy have
been reported in patients with rapidly proliferating tumours
(Remvikos et al, 1989; Bottini et al, 1996; Collecchi et al, 1998), but
other studies have failed to confirm this association (Silvestrini
et al, 1987; Bonadonna et al, 1990; Makris et al, 1997; Ozmen et al,
2001).
The optimum method for assessing response to neoadjuvant
chemotherapy is unclear. Clinical response has traditionally been
used as a surrogate intermediate end point in biological marker
studies although the NSABP-B18 trial, the largest randomised trial
of PST to date, demonstrated that clinical response predicted
disease-free but not overall survival (Fisher et al, 1997). However,
recent reports from The Royal Marsden Hospital show that good
clinical responders (patients with complete clinical response or
residual thickening only) achieve superior overall survival at 10
years compared to poor clinical responders (Chang et al, 1999;
Cleator et al, 2003). Radiological assessment by mammography
and/or ultrasound has been used as a more objective measurement
of response, but correlation with long-term survival has not been
widely studied. Complete pathological response has consistently
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sbeen shown to be associated with improved outcome, but only a
small minority of patients display complete tumour regression
after treatment, reducing its clinical utility as a biological end point
(Sataloff et al, 1995). Patients who achieve a complete pathological
response (pCR) have a statistically significantly superior survival
compared to those with residual invasive carcinoma after PST
(Fisher et al, 1998). Scoring systems that grade incomplete
pathological responses have been devised but have not been
consistently applied. In this study, therefore, a scoring system
devised to grade pathological response has been used alongside
traditional clinical and radiological end points. In the absence of
an optimal method of response assessment, we adopted a
pragmatic approach to measure response by clinical, radiological
and pathological criteria to evaluate whether ER, PgR, HER-2
status or Ki-67 proliferation index before or after treatment predict
response to anthracycline-based PST in women with primary
breast cancer.
MATERIALS AND METHODS
Treatment protocol
During the period September 1995–September 1999, 118 patients
with primary operable (T2–T4, N0 or N1, M0) invasive primary
breast carcinoma were identified (Table 1). Women with
inflammatory breast cancer (T4d) or metastatic disease (M1) were
excluded. All patients underwent diagnostic core biopsy of the
breast tumour to confirm invasive carcinoma before commencing
treatment. Bidimensional clinical tumour measurements were
performed prior to every cycle of treatment. Radiological
measurements of tumour size were recorded before and on
completion of chemotherapy in 94 patients by mammography and/
or breast ultrasound. Patients with responding or stable disease by
clinical criteria received six cycles of anthracycline-based che-
motherapy administered at 21-day intervals. Surgery was per-
formed approximately 1 month after the final cycle of
chemotherapy: 46 women had breast-conserving surgery, 55
required mastectomy and one patient underwent axillary dissec-
tion only. All patients managed by breast-conserving surgery
received post-operative radiation to the residual breast (40Gy in
15 daily fractions over 3 weeks plus 10Gy boost to the tumour bed
in five fractions; n¼32); 14 patients also had the draining lymph
node areas irradiated (50Gy in 25 fractions over 5 weeks). Post-
mastectomy chest wall radiation was delivered to 46 of 55 patients
(32 chest wall only, 14 chest wall and lymph nodes). No patient
received postoperative chemotherapy. Women with ERþ tumours
received 5 years adjuvant Tamoxifen (20mg daily) starting after
surgery.
Five patients developed disease progression by clinical
criteria; four proceeded to immediate surgery. The remaining
patient progressed by clinical and radiological criteria after
three cycles of FEC chemotherapy; she responded to four cycles
of second-line docetaxel and had a near-complete pathological
response at operation (1mm residual invasive carcinoma).
A group of 16 patients who attained a complete clinical
and/or radiological response received radical radiotherapy to the
breast and draining nodal areas, but no surgery. The local research
and ethics committee approved the study prior to patient
recruitment.
Chemotherapy schedules
Patients received a maximum of six cycles of chemotherapy at 21-
day intervals using one of the following regimens (see Table 1): 5-
fluorouracil (5FU) 600mgm
 2, epirubicin 60mgm
 2, cyclopho-
sphamide 600mgm
 2 (FEC); adriamycin 60mgm
 2, cyclopho-
sphamide 600mgm
 2 (AC); cyclophosphamide 600mgm
 2,
adriamycin 60mgm
 2, 5FU 600mgm
 2 (CAF); epirubicin
50mgm
 2, cisplatin 60mgm
 2; 5FU 200mgm
 2day
 1 via Hick-
man line (ECF) or methotrexate 30mgm
 2 (max 45mg),
mitoxantrone 7mgm
 2, mitomycin C 7mgm
 2 (alternate cycles
only) (MMM).
Assessment of response
Clinical and radiological response Standard UICC criteria
(Hayward et al, 1977) were used to categorise objective clinical
and radiological response. Changes in the calculated product
of bidimensional clinical (c) or radiological (r) tumour measure-
ments at diagnosis and on completion of chemotherapy were
recorded. Complete response (CR) was defined as no residual
palpable or radiological abnormality; partial response (PR) as
greater than 50% tumour shrinkage; stable disease (SD) as less
than 50% tumour shrinkage or no change; progressive disease
(PD) as an increase of at least 25%.
Pathological response Many different grading systems for patho-
logical response have been proposed (Chevallier et al, 1993;
Sataloff et al, 1995; Akashi-Tanaka et al, 1996; Honkoop et al, 1998;
Kuerer et al, 1998; Smith et al, 2000), but no standard method for
pathological assessment after chemotherapy has been accepted. A
novel simple scoring system designed to be applied in routine
clinical practice was therefore devised. A consultant histopathol-
ogist (PIR) reviewed all surgical specimens for evidence of
‘histological tumour response’ defined by both (1) an apparent
reduction in tumour cell:stroma ratio and (2) chemotherapy-
induced cytological changes (enlarged cells with finely vacuolated
cytoplasm, an enlarged vesicular nucleus with a prominent single
eosinophilic nucleolus, or an enlarged hyperchromatic dense
Table 1 Patient characteristics
n %
Age: median (years) 48
Age: range (years) 25–78
Menstrual status
Pre 69 59
Peri 19 16
Post 30 25
Clinical TNM stage
T2 61 52
T3 42 36
T4 15 12
Clinical node status
N0 61 52
N1 57 48
Tumour grade
G1 11 14
G2 35 44
G3 33 42
Breast
Right 64 54
Left 53 45
Bilateral 1 1
Chemotherapy regimen
FEC 91 77
AC 9 8
CAF 2 2
ECF 2 2
MMM 14 12
ER, PgR, HER-2, Ki-67 and anthracycline chemotherapy
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snucleus with an irregular outline). The following classification was
used to score histological specimens for pathological response:
pCR – no residual invasive carcinoma; pPR – residual invasive
carcinoma with histological tumour response; pSD – residual
invasive carcinoma with no histological tumour response.
Adequate material from the resected tumour was available for
pathological assessment for 99 of the 102 patients who proceeded
to surgery.
Immunohistochemical technique
Immunohistochemical staining for ER, PgR, HER-2 and Ki-67 was
performed on sections of formalin-fixed paraffin-embedded tissue
from core biopsies and subsequent surgical specimens mounted on
poly-L-lysine slides. Slides were dewaxed and then rehydrated
through graded alcohol (90, 50 and 20%). Following microwave
pre-treatment in 10mM citric acid, monoclonal mouse antibody to
ER, PgR, HER-2 or Ki-67 was applied for 60min at room
temperature using the following dilutions: anti-ER – 1:40, anti-
PgR – 1:60 (Novocastra Laboratories, UK); pre-diluted anti-HER-
2 (Zymed Laboratories, San Francisco, CA, USA); anti-Ki-67 –
1:200 (DAKO Laboratories, UK). Following three rinses in tris-
buffered saline (TBS) and incubation with the secondary antibody,
positive brown staining was detected using a standard avidin and
biotinylated horseradish peroxidase (ABC) technique with 3, 30-
diaminobenzidine (DAB) as the chromogen. Slides were then
counterstained in Mayer’s haematoxylin for 10s, dehydrated in
graded alcohol, mounted and scored. Positive and negative
controls were performed with each stain and paired core biopsies
and surgical specimens from the same patient were stained on the
same run.
Scoring methods
Immunohistochemical scoring was performed, blinded to clinical
and radiological response, using the systems described below.
ER and PgR A validated semi-quantitative scoring system (the
‘Allred score’) was used to assess the proportion (0¼nil, 1o1/100,
2o1/10, 3o1/3, 4o2/3, 542/3) and intensity (0¼no staining,
1¼weak, 2¼intermediate, 3¼strong) of stained cells (Allred et al,
1990). A total score (range 0, 2–8) of 3 or more defined positive
staining.
HER-2 A standard scoring system to assess both the intensity
and proportion of membrane staining was used: 0 – no membrane
staining or membrane staining in less than 10% of tumour cells;
1
þ – faint barely perceptible membrane staining in more than 10%
of tumour cells visible in part of the membrane only; 2
þ – weak to
moderate staining of the entire membrane in more than 10% of
tumour cells; 3
þ – strong staining of the entire membrane in more
than 10% of tumour cells. Tumours scored 3þ were classed
positive.
Ki-67 Positive and negatively stained cells were counted on a
minimum of 10 randomly selected  40 high-power fields
containing representative sections of tumour. The Ki-67 prolifera-
tion index (the fraction of proliferating cells) was calculated (i.e.
number of positively stained cells as a percentage of the total cell
count).
Statistical methods
Statistical analysis was carried out using JMP version 5.0. (SAS
Institute Inc.). Associations between ordinal variables were
assessed using w
2 analyses or the Fischer Exact Test in the case
of 2 2 variables. Analyses involving Ki-67 as a continuous
variable were investigated using ANOVA.
RESULTS
Response rates
A median of six cycles of chemotherapy was administered (range
2–6). At the time of analysis, 118, 94 and 99 patients were
evaluable for clinical, radiological and pathological response,
respectively. The overall objective clinical and radiological
response rates (CR þ PR) to preoperative chemotherapy were
78 and 72%, respectively. In all, 40% of patients attained a clinical
CR. However, the pathological response rate was just 38%,
including eight complete pathological responders (8%) among 99
assessable patients. Of the eight patients who achieved a complete
pathological response, one was classified as a partial clinical and
radiological responder and a further two achieved a partial
radiological response; the remainder were complete responders
by nonpathological criteria. Eight patients (7%) developed
progressive disease during chemotherapy by clinical (five) and/
or radiological (five) criteria; all the remaining 29 women had
stable disease on clinical (21) and/or imaging (21) assessments
(Table 2).
Figure 1 shows the relationships between the three response end
points and illustrates that significant difference in response
categorisation exists depending on the chosen end point. However,
when the clinical and worst radiological response data (ultrasound
or mammography) were condensed to responders (CR or PR) vs
nonresponders (SD or PD), there was almost complete agreement
(98.5%) in classification of responders but a third of radiological
nonresponders had a clinical response.
Pretreatment biological parameters: inter-relationships
and correlation with clinico-pathological features
The median positivity for Ki-67 was 24.9%. (range 4.1–58.5%).
There was a wide range of expression patterns for ER and PgR.
Overall, 63.6% of tumours were classified as ERþ and 55.1% were
PgRþ. The majority of ERþ (77%) and PgRþ (58%) specimens
showed expression in greater than 1
3 of cells with a wide range of
staining intensity; this resulted in a wide variation in the total
Allred score spanning all categories from 2 to 8 (data not shown).
Positive (3þ) HER-2 staining was seen in 16% of tumours; 15
tumours (13%) showed weak to moderate staining (2þ) deemed
negative for the purpose of these analyses.
The inter-relationships between the four biological markers,
pretreatment tumour size and pathological node status are shown
in Table 3. There was a significant correlation between ER and PgR
Table 2 Response rates [n (%)] by method of assessment
Assessment n ORR
a CR PR SD PD
Clinical 118 92 (78%) 47 (40%) 45 (38%) 21 (18%) 5 (4%)
Radiological 94 68 (72%) 18 (19%) 50 (53%) 21 (22%) 5 (5%)
Pathological 99 38 (38%) 8 (8%) 30 (30%) 61 (62%) —
aORR: overall response rate¼CR+PR.
ER, PgR, HER-2, Ki-67 and anthracycline chemotherapy
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tumours showed positivity for both steroid receptors. Higher
Ki-67 proliferation indices were associated with PgR  tumours
(PgR  median 28.3%, PgRþ 22.9%; P¼0.04). A nonsignificant
trend towards higher cell proliferation in pathologically node-
positive tumours was observed (pathologically node negative,
median Ki-67 19.6%, node positive 25.8%; P¼0.09). There were no
relationships between HER-2 expression and the other biological
markers.
No relationship was seen between hormone receptor status and
primary tumour size or pretreatment lymph node involvement. Ki-
67 proliferation index was similar in both small and larger
tumours. Clinically, node-negative patients (23 out of 61) were
more likely to overexpress HER-2 than node-positive tumours (11
out of 57; P¼0.04) (data not shown).
Pretreatment biological parameters: correlation with
treatment response
None of the pretreatment biopsy parameters correlated with any
clinical, radiological or pathological response measures (Table 4).
Combining the biological parameters into ‘good’ (ERþ and
PgRþ, low Ki-67) or ‘bad’ (ER  and PgR , high Ki-67) risk
prognostic groups also had no impact in predicting clinical
response (data not shown).
Changes in biological parameters during treatment
Figure 2 shows the changes in each biological parameter after PST.
The steroid receptors showed only modest alterations during
treatment. Only 13 and 25 tumours showed a shift in ER or PgR
Allred score of more than 1, respectively. This resulted in three
tumours changing their ER classification (positive to negative or
vice versa), while seven specimens showed re-classification of their
overall PgR score after chemotherapy. The median Ki-67
proliferation indices before and after treatment were 24.9 and
18.1%, respectively (P¼0.002). Expressing the change as a
function of the pretreatment Ki-67 index resulted in a median
reduction in Ki-67 index after treatment of 21.2%. Of 84 evaluable
patients, 47 (60%) showed little or no change (710% of %
change), 10 patients (12%) showed an increase of 450% of the
original index and 24 (29%) showed a reduction of 450%. Strong
or moderate HER-2 staining (2þ or 3þ) at diagnosis persisted in
every case after chemotherapy although HER-2 positivity (3þ
cases only) changed in nine cases: five 2þ tumours were scored
3þ at operation and four 3þ tumours reverted to 2þ at surgery.
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Figure 1 Correlation between clinical, radiological and pathological
response. Solid bars represent CR; shaded bars PR and open bars NR.
Table 3 Relationship between clinical and biological variables
T2 T3/4 P
ER+ 39/61 (64.0%) 36/57 (63.2%) NS
PgR+ 34/61 (55.7%) 31/57 (54.4%) NS
HER-2+ 21/61 (34.4%) 13/57 (22.8%) NS
Ki-67 median 25.8% 23.1% NS
ER  ER+
PgR+ 9/43 (20.9%) 56/75 (74.7%) o0.0001
HER-2+ 14/43 (32.6%) 20/75 (26.7%) NS
Ki-67 median 28.6% 23.1% NS
HER-2  HER-2+
ER+ 55/84 (65.5%) 20/34 (58.8%) NS
PgR+ 49/84 (58.3%) 16/34 (47.1%) NS
Ki-67 median 25.4% 23.5% NS
PgR  PgR+
Ki-67 median 28.3% 22.9% 0.04
Table 4 Response rates (CR + PR) by biopsy marker status
Clinical
response (%)
Radiological
response (%)
Pathological
response (%)
All patients 78 72 38
ER+ 81 73 34
ER  72 71 46
P-value 0.25 0.81 0.29
PgR+ 83 78 31
PgR  72 65 47
P-value 0.18 0.17 0.15
HER-2+ 71 62 44
HER-2  81 77 36
P-value 0.23 0.15 0.51
Ki-67 high 73 74 39
Ki-67 low 81 70 38
P-value 0.38 0.81 1.0
Each parameter was dichotomised as described in the text or above and below the
median value for Ki-67.
ER, PgR, HER-2, Ki-67 and anthracycline chemotherapy
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treatment response
None of the biological markers measured in the surgical specimen
correlated with any of the treatment response end points.
Changes in biological parameters: correlation with
treatment response
Changes in hormone receptor status or HER-2 did not predict
treatment response by pathological, clinical or radiological criteria.
Overall, there was no significant difference in the reduction in Ki-
67 after treatment between responders and nonresponders when
assessed by clinical, radiological or pathological criteria. However,
patients with the greatest reduction in cell proliferation after
chemotherapy were more likely to achieve a pathological response.
Of the nine patients displaying a 75% or more fall in Ki-67 index
after treatment, seven (77.8%) were pathological responders;
conversely, only 20 of the remaining 75 evaluable patients
(26.7%) with less extreme decreases in cell proliferation responded
by histological criteria (P¼0.004).
DISCUSSION
The identification of reliable predictive and prognostic factors for
PST in operable breast cancer remains a challenge. In the same way
that ER and PgR status can predict sensitivity to endocrine
therapy, reliable markers of chemosensitivity would help select
those patients most likely to benefit from primary chemotherapy.
More importantly, the early identification of nonresponders would
allow these patients to be spared the unnecessary toxicity of
ineffective chemotherapy and be offered alternative more effective
treatment regimens tailored to the biological characteristics of the
tumour.
Previous studies have focused on the ability to predict clinical
tumour shrinkage, despite the fact that local response is a crude
measure dependent on several variables including primary tumour
size, oedema, necrosis and subjective variation in tumour
measurements. Clinical assessment frequently overestimates tu-
mour size (Fornage et al, 1987; Pain et al, 1992; Forouhi et al, 1994;
Meden et al, 1995; Allen et al, 2001). Radiological assessment of
maximum tumour dimensions by ultrasound or mammography is
often performed to assess response and correlates better with
histological tumour size than clinical measurements (Allen et al,
2001; Fiorentino et al, 2001). However, complete pathological
response is the best predictor of long-term survival (Fisher et al,
1998). In the absence of a universally accepted optimal end point,
this study therefore analysed the ability of simple biological
markers to predict clinical, radiological and pathological response
to treatment.
The clinical response (CRþPR) and complete pathological
response (pCR) rates of 78 and 8%, respectively, seen in this series
are consistent with those reported in larger randomised trials of
PST (Bonadonna et al, 1990; Mauriac et al, 1991; Belembaogo et al,
1992; Fisher et al, 1997; Makris et al, 1998). The rates of positive
staining for ER, PgR, HER-2 and Ki67 are also in accordance with
expectations. Steroid hormone receptor status, HER-2 staining and
Ki-67 index did not vary with tumour size or lymph node
involvement, in keeping with previous observations (Bouzubar
et al, 1989; Bottini et al, 1996).
In contrast with previous reports (Bonadonna et al, 1990; Bottini
et al, 1996; Chang et al, 1999; Colleoni et al, 2000), clinical
response rates to PST were higher in hormone receptor-positive
tumours in this cohort, although the difference did not reach
statistical significance. It is worthy of note that patients with
hormone receptor-positive tumours in this study received
chemotherapy followed by sequential adjuvant tamoxifen, rather
than primary concurrent chemoendocrine treatment used in
earlier reports (Makris et al, 1998; Chang et al, 1999). Conse-
quently, any observed changes in marker status must be attributed
to the direct effects of chemotherapy alone since the confounding
influence of synchronous endocrine treatment has been excluded.
There is some evidence from prospective studies that HER-2
overexpression predicts sensitivity to adjuvant anthracycline
chemotherapy (Muss et al, 1994; Clahsen et al, 1998; Paik et al,
1998; Thor et al, 1998) and resistance to tamoxifen (Nicholson et al,
1993; Leitzel et al, 1995; Carlomagno et al, 1996; Yamauchi et al,
1997). However, in this series, a nonsignificant trend towards
poorer clinical and radiological response was seen in HER-2
overexpressors, although no difference in pathological response
rates was observed. HER-2 expression was more common in ER 
tumours (33 vs 27%) although the difference did not reach
statistical significance. It should be noted that the dose of
epirubicin used in this study (60mgm
 2) may be considered
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treatment.
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ssuboptimal, particularly for HER-2þ tumours. However, this was
the standard dose in our institution at the time of the study.
These data confirm that no single pretreatment or postche-
motherapy biological parameter predicts response by clinical,
radiological or pathological criteria. With longer follow-up, it will
be possible to correlate response by the three different assessment
modalities with long-term survival and ultimately decide which, if
any, of the methods of assessing response is best placed to act as a
surrogate marker for overall survival in this cohort.
It is unlikely that any single biological marker will ever be able
to reliably discriminate between responders and nonresponders,
but combinations of marker expression may have greater
predictive value. Intuitively, steroid receptor-negative tumours
with a high proliferative rate may be expected to confer a worse
prognosis. In order to test this hypothesis, we arbitrarily grouped
tumours into those with a combination of ‘good’ (ERþ and
PgRþ, low Ki-67) or ‘bad’ (ER  and PgR  and high Ki-67)
biological parameters. However, these arbitrary groups of markers
also failed to discriminate between responders and nonresponders.
Although the potential effects of PST on the biological
characteristics of primary breast cancers have not been widely
studied, clinical decisions regarding adjuvant treatment after
primary chemotherapy are frequently based on immunohisto-
chemical analysis performed on surgical specimens pretreated with
cytotoxic therapy. In this series, negative (0 or 1) and strong or
moderate (2þ or 3þ) HER-2 staining persisted after chemother-
apy in every case. This is consistent with earlier observations that
HER-2 status remains unchanged after PST (Bottini et al, 1996;
Taucher et al, 2003b). In this series, some subtle changes in HER-2
staining were seen after chemotherapy. In nine of 118 cases (8%),
HER-2 status changed from positive to negative or vice versa (five
cases 2þ to 3þ; four tumours 3þ to 2þ). Based on these data,
we recommend that patients with HER-2 scores of 0 or 1 on
pretreatment biopsies do not require repeat assay after che-
motherapy; however, patients with moderate or strong staining
should undergo FISH analysis on a post-treatment tissue block to
accurately determine the post-chemotherapy HER-2 status.
Hormone receptor expression was unchanged after treatment in
the majority of tumours in this cohort, but a significant minority
(10 cases, 8%) displayed a shift in ER or PgR classification at the
time of surgery. In five of the 10 tumours in which changes in
receptor status were described, negative staining on pretreatment
core biopsies was scored positive after chemotherapy. In the
remaining five cases, hormone receptor-positive core biopsies
stained negative at operation. Although these observations may
reflect sampling error within heterogeneous tumours, immunos-
taining on needle core biopsies in a previously reported series of
236 patients treated without intervening chemotherapy was highly
representative of hormone receptor status in the entire resected
tumour (Taucher et al, 2003a), suggesting that sampling error does
not account for the observed hormone receptor ‘upregulation’ seen
in some cases.
Some groups investigating the modulation of steroid receptor
status by PST reported no significant changes in ER or PgR
(Hawkins et al, 1990; Bottini et al, 1996; Schneider et al, 2000) after
primary chemotherapy. The data presented here concur with two
earlier small studies in which 10% (Lo et al, 1994) and 33% (Jain
et al, 1996) of breast cancers expressed altered steroid receptor
status after PST. A recently published comprehensive analysis of
hormone receptor immunochemistry in 450 breast cancer patients
confirmed these observations in a larger cohort and speculated on
a possible hypothesis for the mechanism of changes in ER and PgR
status after PST (Taucher et al, 2003a). Among 191 patients
receiving PST, 14 of 100 ERþ tumours (14%) stained ER  after
treatment, representing a statistically significant shift of ERþ to
ER  status as a direct result of PST (P¼0.02). Half of these
patients (7 out of 14) were pre-menopausal, suggesting that PST
may be exerting an endocrine effect by rendering women post-
menopausal after chemotherapy. Our data are consistent with this
hypothesis: four of the five patients displaying decreases in
hormone receptor positivity after chemotherapy were premeno-
pausal at diagnosis. Since potentially curative adjuvant hormone
therapy is prescribed on the basis of hormone receptor
immunostaining, we recommend that patients with ER  or PgR 
status on pretreatment core biopsies should undergo repeat assay
on the resected surgical specimen.
The observation that the median Ki-67 index was significantly
lower after treatment in this cohort suggests that chemotherapy is
exerting a true anti-proliferative effect on tumours in vivo. Both
primary endocrine (Clarke et al, 1993) and cytotoxic treatments
(Daidone et al, 1991; Gardin et al, 1994) inhibit tumour growth.
Tumour cell proliferation has been shown to be a prognostic
marker in some reports (Remvikos et al, 1989; Bonetti et al, 1996;
Chevillard et al, 1996), but data on its predictive value are
conflicting. S-phase fraction, proliferating cell nuclear antigen and
thymidine labelling index predict overall survival (Clayton, 1991;
Fisher et al, 1991; Merkel et al, 1993) and response (Collecchi et al,
1996; Bottini et al, 1998; Nishimura et al, 2002), but not disease-
free survival (Bianchi et al, 1993; Pisansky et al, 1993; Tahan et al,
1993) in patients treated with primary surgery or chemotherapy.
Baseline Ki-67 index did not predict clinical response in this
cohort of patients. This is consistent with other studies
(Bonadonna et al, 1990; Makris et al, 1997), but in contrast to
data from other groups, which suggested that S-phase fraction
(Remvikos et al, 1989), Ki-67 index (Bottini et al, 1996) or
thymidine labelling index (Collecchi et al, 1998) predict clinical
tumour shrinkage. To the best of our knowledge, pathological
response has not been formally assessed in previous studies
analysing the predictive value of Ki-67 before and after PST. In this
study, pretreatment cell proliferation failed to predict pathological
response. This suggests that chemosensitivity is not simply a
function of the baseline rate of tumour cell proliferation, and
supports the theory that some rapidly proliferating tumours are
inherently chemoresistant. However, tumours that displayed a
large reduction in Ki-67 index after chemotherapy were more
likely to achieve a pathological response: 78% of patients (seven
out of nine) with falls of 475% in Ki-67 after treatment were
pathological responders compared to 20 out of 75 (27%) of those
with less extreme falls in Ki-67. These findings have not been
previously reported. Intuitively, this observation suggests that the
antiproliferative and proapoptotic effects of chemotherapy are
indeed translated into a measurable histological response.
Like many studies in this field, this work is hindered by the fact
that complete pathological response and clinical progression – the
two scenarios that clinicians would most like to be able to predict –
are relatively uncommon events. The majority of patients achieve a
PR by clinical or radiological criteria and nearly two-thirds showed
SD by pathological assessment. Consequently, large studies are
required if reliable predictive markers are to be identified.
In conclusion, the baseline biological characteristics of primary
breast tumours analysed in this study did not predict response to
treatment by any modality of assessment. However, patients with
the greatest reductions in tumour cell proliferation on completion
of chemotherapy were most likely to achieve a pathological
response. With longer follow-up, it will be possible to establish if
chemotherapy-induced changes in cell proliferation have prog-
nostic value, and to determine whether the pathological response
scoring system described here can be used as a surrogate end point
for long-term clinical outcome.
Novel markers that relate to the actions of chemotherapy drugs
are needed if reliable predictive markers are to be identified. One
such example is topoisomerase IIa, a molecular target for
anthracyclines. A recent study showed that strong topoisomerase
IIa staining is an independent predictor of clinical tumour
regression (MacGrogan et al, 2003); a confirmatory study is
underway on this data set. In the meantime, it is imperative that
ER, PgR, HER-2, Ki-67 and anthracycline chemotherapy
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encourage recruitment into parallel biological marker studies so
that more powerful data sets can continue the search for
favourable and unfavourable biological profiles that may ulti-
mately help clinicians individualise treatments. Meanwhile, the
ability to study the patterns of expression of thousands of
candidate genes simultaneously using new micro-array technolo-
gies (Perou et al, 2000; Chang et al, 2003) may rapidly surpass
retrospective analyses using immunohistochemistry in the con-
tinuing search for predictive and prognostic factors.
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